Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.

ABSTRACT:

Background

Patients with uncontrolled type 2 diabetes mellitus (T2DM) are a priority group for intensified therapy without weight gain and with low risk of hypoglycaemia.

Objective

This study evaluates the cost effectiveness of insulin degludec plus liraglutide (IDegLira, Xultophy^®) compared with six potential intensification treatment options for patients with T2DM that is uncontrolled with basal insulin.

Methods

The Swedish Institute for Health Economics (IHE) Cohort Model of Type 2 Diabetes was used with Swedish input data, a 40-year time frame and a societal perspective. The comparators for treatment intensification included insulin glargine, neutral protamine Hagedorn (NPH) insulin, insulin aspart plus either glargine or NPH, and liraglutide plus eithe

SUBMITTER: Ericsson A 

PROVIDER: S-EPMC5343072 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature